NCT03368118View on ClinicalTrials.gov

Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 20, 2018

Primary Completion Date

July 12, 2022

Study Completion Date

August 15, 2022

Conditions
Ulcerative Colitis
Interventions
DRUG

ABX464

All subjects will receive ABX464 given at 50 mg o.d for an overall period of 48 months.

Trial Locations (1)

3000

Department of Gastroenterology - University hospitals Leuven, Leuven

Sponsors

Lead Sponsor

Abivax S.A.
All Listed Sponsors
collaborator

Orion Corporation, Orion Pharma

INDUSTRY

lead

Abivax S.A.

INDUSTRY